Actuate TherapeuticsACTU -12.50%14 Cash Ratio is 1.72 as of Mar. 2026, which is 76% above its 10-year median of 0.98. GuruFocus rates ACTU with a GF Score™ of 14/100. Among 1,384 Biotechnology companies, Actuate Therapeutics ranks worse than 63.01% on this metric.
Actuate Therapeutics has a Cash Ratio of 1.72. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Actuate Therapeutics's Cash Ratio or its related term are showing as below:
ACTU'
s Cash Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.98 Max: 4.71
Current: 1.72
During the past 4 years, Actuate Therapeutics's highest Cash Ratio was 4.71. The lowest was 0.02. And the median was 0.98.
ACTU's Cash Ratio is ranked worse than 63.01% of 1384
companies
in the Biotechnology industry
Industry Median: 2.955
vs ACTU: 1.72
Actuate Therapeutics (NAS:ACTU) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Actuate Therapeutics Cash Ratio Related Terms
Actuate Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Actuate Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Actuate Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Actuate Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Actuate Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Actuate Therapeutics (ACTU) has a Cash Ratio of 1.72 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Actuate Therapeutics and its competitors. This is 76% above median its historical median of 0.98. Over the past decade, Actuate Therapeutics' Cash Ratio has ranged from 0.02 to 4.71. According to the industry distribution chart, Actuate Therapeutics ranks #872 out of 1384 companies in the Biotechnology industry, placing it in the top 63%.
Is Actuate Therapeutics' Cash Ratio too high?
Actuate Therapeutics' current Cash Ratio of 1.72 is 76% above median its 10-year median of 0.98. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 4.71. The Biotechnology industry median Cash Ratio is 2.96. Actuate Therapeutics' value of 1.72 is 41.8% below this industry median. Based on the distribution chart, Actuate Therapeutics ranks #872 out of 1384 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Cash Ratio compare to RNXT and ESLA?
According to the Biotechnology industry distribution chart, Actuate Therapeutics ranks #872 out of 1384 companies for Cash Ratio. This places Actuate Therapeutics in the lower half of its industry. The industry median Cash Ratio is 2.96. Actuate Therapeutics' value of 1.72 is 41.8% below this benchmark. Historically, Actuate Therapeutics' own Cash Ratio has ranged from 0.02 to 4.71 over the past decade. While the company's 10-year median is 0.98 vs. the industry median of 2.96, Actuate Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Actuate Therapeutics's current Cash Ratio of 1.72 is 41.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Actuate Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actuate Therapeutics's current Cash Ratio is 1.72, which is 76% above median its own 10-year median of 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Cash Ratio of 1.72. The current Cash Ratio is 1.72, which is 76% above median its 10-year median of 0.98 and 41.8% below the Biotechnology industry median of 2.96. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Cash Ratio is 1.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score
Get the complete analysis for ACTU
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACTU has been successfully added to your 
